Altamira Therapeutics Joins Forces with Univercells Group to Advance Nanoparticle-Delivered mRNA Vaccines
HAMILTON, BERMUDA, March 25, 2024 - Altamira Therapeutics Ltd. (Altamira) (Nasdaq:CYTO), a leading provider of nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, has announced a promising collaboration with Univercells Group (Univercells). This partnership aims to assess the effectiveness of Altamira’s proprietary SemaPhore platform for the delivery of mRNA vaccines. Univercells, a global life sciences company renowned for creating platforms that enable the development and manufacturing of biologics, including mRNA vaccines and therapeutics in an accessible, scalable, and cost-efficient manner, will be an invaluable partner in this endeavor.
mRNA vaccines have garnered significant attention in recent years due to their potential to revolutionize disease prevention and treatment. These vaccines work by introducing a small fragment of the virus’s genetic material (mRNA) into the body, allowing cells to produce a harmless part of the targeted pathogen. This process triggers an immune response, effectively training the body to recognize and neutralize the virus in case of future exposure. While mRNA vaccines offer numerous advantages such as rapid development, adaptability, and reduced production costs, their delivery to specific target tissues remains a challenge.
Altamira Therapeutics specializes in the development of nanoparticle-based technologies that overcome the limitations of traditional delivery methods. By utilizing the SemaPhore platform, Altamira aims to enhance the delivery efficiency of mRNA vaccines to extrahepatic (beyond the liver) tissues. This partnership with Univercells, known for their expertise in simplifying and optimizing biologics production, aligns perfectly with Altamira’s mission to make mRNA vaccines accessible to a broader population.
The SemaPhore platform developed by Altamira enables nanoparticles to effectively transport mRNA payloads to target tissues. These nanoparticles provide protection to the mRNA molecules, ensuring their stability and direct delivery to the desired cells. By enhancing target tissue specificity, this technology has the potential to enhance the efficacy of mRNA vaccines significantly, supporting their adoption as a mainstream preventive measure against various diseases.
Univercells brings its extensive experience in developing scalable and cost-efficient manufacturing platforms to the collaboration. The company’s innovative approach has consistently paved the way for the production of high-quality biologics at reduced costs. By joining forces with Univercells, Altamira aims to optimize and streamline the manufacturing process, ensuring maximum scalability and cost-effectiveness for the production of mRNA vaccines.
Both Altamira and Univercells are striving to address the current challenges in mRNA vaccine delivery, particularly to extrahepatic tissues. The collaboration aims to evaluate the compatibility of Altamira’s SemaPhore platform with Univercells’ manufacturing processes, ensuring the seamless integration of mRNA vaccine production and delivery. This comprehensive assessment will leverage both companies’ expertise and resources to propel the development and accessibility of mRNA vaccines on a global scale.
The successful outcome of this collaboration has the potential to open new frontiers in the field of mRNA vaccines. By efficiently delivering these vaccines to target tissues, this joint effort could significantly enhance the efficacy and accessibility of preventive measures against a wide range of diseases. Moreover, the optimized manufacturing process resulting from this partnership has the potential to revolutionize mRNA vaccine production, enabling mass production at affordable costs.
In summary, Altamira Therapeutics’ collaboration with Univercells Group offers exciting prospects for the advancement of nanoparticle-delivered mRNA vaccines. By combining Altamira’s cutting-edge SemaPhore platform and Univercells’ expertise in scalable and cost-efficient manufacturing, this partnership holds tremendous promise in overcoming the limitations of current mRNA vaccine delivery methods. As research and development progress, the successful integration of this technology could reshape the landscape of disease prevention, making mRNA vaccines more accessible, effective, and affordable across the globe.
Comments